Meta-Analysis of Creatine for Neuroprotection Against Parkinson's Disease
Attia, Ahmed H, Gadelkarim M, Morsi M, Morsi M, Awad K, Elnenny M, Ghanem E, El-Jaafary S, Negida A
CNS & neurological disorders drug targets · 10 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Meta-analysis (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2016-12-02 · CNS Neurol Disord Drug Targets · vol. 16 · issue 2 · pp. 169–175
- Publisher
- Bentham Science Publishers
- Cited
- 19 citations · more than 55% of similar papers · 0.7× the field average
- References
- 0 works
- Access
- Paywalled
- Research areas
- Parkinson's Disease Mechanisms and Treatments · Muscle metabolism and nutrition · Nutrition and Health in Aging
- Keywords
- Neuroprotection, Parkinson's disease, Creatine, Meta-analysis, Medicine, Stroke (engine), Disease, Randomized controlled trial, Clinical trial, Internal medicine
- MeSH
- animals, humans, parkinson disease, creatine, antiparkinson agents, neuroprotective agents, randomized controlled trials as topic
9 authors
From EG
- Attia AttiaScientific Research Group in Egypt
- Hussien AhmedScientific Research Group in Egypt
- Mohamed GadelkarimScientific Research Group in Egypt
- Mahmoud MorsiScientific Research Group in Egypt
- Kamal AwadScientific Research Group in Egypt
- Mohamed ElnennyScientific Research Group in Egypt
Abstract
Background
Creatine is an antioxidant agent that showed neuroprotective effects in animal models of Parkinson's disease (PD). Creatine was selected by the National Institute of Neurological Disorders and Stroke as a possible disease modifying agent for Parkinson's disease. Therefore, many clinical trials evaluated the efficacy of creatine for patients with PD. The aim of this systematic review and meta-analysis is to synthesize evidence from published randomized controlled trials (RCTs) about the efficacy of Creatine for patients with PD.
Methods
We followed PRISMA statement guidelines during the preparation of this systematic review and meta-analysis. A computer literature search for PubMed, EBSCO, web of science and Ovid Midline was carried out. We included RCTs comparing creatine with placebo in terms of motor functions and quality of life. Outcomes of total Unified Parkinson's Disease Rating Scale (UPDRS), UPDRS I, UPDRS II, and UPDRS III were pooled as mean difference (MD) between two groups from baseline to the endpoint. Statistical heterogeneity was assessed by visual inspection of the forest plot and measured by chi-square and I square tests.
Results
Three RCTs (n=1935) were included in this study. The overall effect did not favor either of the two groups in terms of: UPDRS total score (MD 1.07, 95% CI [3.38 to 1.25], UPDRS III (MD 0.62, 95% CI [2.27 to 1.02]), UPDRS II (MD 0.03, 95% CI [0.81 to 0.86], or UPDRS I (MD 0.03, 95% CI [0.33 to 0.28]).
Conclusion
Current evidence does not support the use of creatine for neuroprotection against PD. Future well-designed, randomized controlled trials are needed.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.